TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12963672
Drug: Family-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused therapy (FFT) with pharmacotherapy
Study: 12963672
Drug: Crisis management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisis management (CM) with pharmacotherapy
Study: 8695248
Drug: Ondansetron (OND)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (OND) 8 mg x 3 i.v. on day 1 and 8 mg x 2 orally on day 2
Study: 8695248
Drug: Granisetron (GRA)
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron (GRA) 3 mg i.v. on day 1
Study: 1809589
Drug: Augmented betamethasone
Normalized name: Augmented betamethasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented betamethasone dipropionate (ABD) ointment 0.05% applied in an intermittent pulse dose regimen (three consecutive applications 12 h apart, once a week for a maximum treatment period of 6 months)
Study: 3891159
Drug: Induction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of a hypnotic state
Study: 30464392
Drug: Fimasartan/Rosuvastatin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan/Rosuvastatin fixed-dose combination (120 mg fimasartan and 20 mg rosuvastatin)
Study: 30464392
Drug: Separate co-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate co-administration of fimasartan and rosuvastatin
Study: 22264499
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g XOS
Study: 22264499
Drug: INU‐XOS (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: INU‐XOS (3 g inulin + 1 g XOS)
Study: 21457067
Drug: Matsuda insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matsuda insulin sensitivity index (MISI)
Study: 18095238
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg/day) + Metformin (2 g/day)
Study: 18095238
Drug: Sulphonylurea (Glibenclamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphonylurea (Glibenclamide 5 mg/day or Gliclazide 80 mg/day) + Metformin (2 g/day)
Study: 8832493
Drug: MDI A
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI A (HFA-134a inhalation aerosol system), 4 inhalations four times per day for 14 days
Study: 8832493
Drug: MDI A
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI A (HFA-134a inhalation aerosol system), 8 inhalations four times per day for 14 days
Study: 8832493
Drug: MDI A
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI A (HFA-134a inhalation aerosol system)
Study: 31048645
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous antibiotics once on the day of surgery and oral antibiotics for 4 days (Control group)
Study: 31048645
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative antibiotics (Experimental group)
Study: 29507938
Drug: Daily antituberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily antituberculosis therapy
Study: 29507938
Drug: Part-daily antituberculosis
Normalized name: TRICARE PRENATAL 2-PART DAILY PRENATAL VITAMIN SYSTEM KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part-daily antituberculosis therapy
Study: 29507938
Drug: Intermittent antituberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent antituberculosis therapy
Study: 27764725
Drug: H-BE (600-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-BE (600-mg total anthocyanins)
Study: 11878655
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol (40-60 mg kg-1 single dose)
Study: 11878655
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol (14-20 mg kg-1 repeat dosing)
Study: 11878655
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol (10-20 mg kg-1 single dose)
Study: 10342698
Drug: Improved sexually-transmitted
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved sexually-transmitted disease (STD) treatment services
Study: 7774469
Drug: PEG‐ELS +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐ELS + oral metoclopramide (n = 99)
Study: 7774469
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate (n = 106)
Study: 2330929
Drug: Cold-recombinant bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-recombinant bivalent A vaccine
Study: 2330929
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated vaccine
Study: 31838622
Drug: Magnesium and
Normalized name: Calcium, Magnesium and Zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium and Ketamine (Mg + K)
Study: 26652098
Drug: Chlorhexidine solution
Normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine solution and swab
Study: 24299607
Drug: Xinfeng Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng Capsule
Study: 24299607
Drug: Placebo (imitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (imitation Xinfeng Capsule)
Study: 19165109
Drug: SilvaSorb Gel
Normalized name: SILVASORB GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: SilvaSorb Gel
Study: 19165109
Drug: Silvadene silver
Normalized name: silver sulfadiazine Topical Cream [Silvadene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silvadene silver sulfadiazine cream
Study: 9337167
Drug: Preincisional or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincisional or intraincisional infiltration with metronidazole (0.915 g metronidazole disodium phosphate injection in 100 mL 0.9% normal saline, injected 60-80 mL into subcutaneous tissue and muscle).
Study: 9337167
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received intravenous injection of metronidazole disodium phosphate and cephazolin postoperatively.
Study: 8441838
Drug: Dopamine IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine IV at 2 micrograms/kg/min in 0.45% NaCl at 100 mL/h for 2 h during and after cardiac catheterization
Study: 8441838
Drug: 0.45% NaCl
Normalized name: LVP solution Dextrose 5% with 0.45% NaCl intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% NaCl IV at 100 mL/h (Group 1)
Study: 8441838
Drug: Dopamine IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine IV at 2 micrograms/kg/min in 0.45% NaCl at 100 mL/h (Group 2)
Study: 3154147
Drug: 16-week treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-week treatment program for wife assault
Study: 30134136
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g administered intravenously)
Study: 23796946
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2.2 g/day LC-n3-FA)
Study: 15001305
Drug: Home IV
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home IV therapy
Study: 15001305
Drug: Hospital IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital IV therapy
Study: 9329413
Drug: Prednisone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1 mg/kg per day orally) for 5 days
Study: 9329413
Drug: Bronchodilator reversibility
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator reversibility testing with albuterol
Study: 29362512
Drug: Aripiprazole (APZ)
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole (APZ) titrated to 15 mg
Study: 9013228
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (100 mg/day)
Study: 4008128
Drug: Low-dose marijuana
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose marijuana cigarettes
Study: 4008128
Drug: High-dose marijuana
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose marijuana cigarettes
Study: 27028911
Drug: Doxycycline (12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (12-week oral course)
Study: 27028911
Drug: Clarithromycin plus
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin plus hydroxychloroquine (12-week oral course)
Study: 24295850
Drug: 10 day
Normalized name: DexPak 10 Day Taperpak
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 day sequential therapy (SEQ)
Study: 24295850
Drug: 10 day
Normalized name: DexPak 10 Day Taperpak
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 day modified bismuth quadruple therapy (QUAD)
Study: 11450675
Drug: Single 200-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 200-mg dose of doxycycline
Study: 9549926
Drug: Antithrombotic drugs
Normalized name: Heparin group antithrombotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic drugs (e.g., aspirin)
Study: 2903170
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (1600 mg/day) for 6 days
Study: 16971821
Drug: 12-week outpatient
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week outpatient treatment
Study: 14594917
Drug: Cognitive-behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural treatment (CBT) programme
Study: 10511327
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (24 mg of beta-carotene, 1000 mg of ascorbate, and 800 IU of alpha-tocopherol daily for 12 weeks)
Study: 10511327
Drug: Placebo (baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (baseline and post-treatment phases)
Study: 7865226
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg and 600 mg)
Study: 7865226
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (1 mg and 7 mg)
Study: 7286357
Drug: Clofazimine 100
Normalized name: clofazimine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine 100 mg daily with sun exposure
Study: 7286357
Drug: Clofazimine 100
Normalized name: clofazimine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine 100 mg daily without sun exposure
Study: 27292774
Drug: Amoxicillin (AMX)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (AMX) at 10 mg/kg body weight (b.w.)
Study: 27292774
Drug: Amoxicillin (AMX)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (AMX) at 20 mg/kg body weight (b.w.)
Study: 19608812
Drug: Fosaprepitant 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant 200 mg IV
Study: 19608812
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg per os
Study: 17512226
Drug: PTFE patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTFE patch insertion
Study: 17512226
Drug: Redo saphenofemoral
Normalized name: Redox-phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Redo saphenofemoral ligation and great saphenous vein stripping with PTFE patch
Study: 17512226
Drug: Redo saphenofemoral
Normalized name: Redox-phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Redo saphenofemoral ligation and great saphenous vein stripping without PTFE patch
Study: 17512226
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (with and without PTFE patch)
Study: 7802219
Drug: Single medial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single medial injection using prilocaine 3% with felypressin
Study: 7802219
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections using prilocaine 3% with felypressin
Study: 3293874
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day carprofen
Study: 3293874
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day carprofen
Study: 3293874
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day carprofen
Study: 3293874
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day carprofen
Study: 3293874
Drug: Carprofen concentrations
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carprofen concentrations greater than 10 micrograms/ml
Study: 3293874
Drug: Carprofen concentrations
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carprofen concentrations below 1.9 micrograms/ml
Study: 3293874
Drug: Carprofen (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen (various doses)
Study: 3293874
Drug: Carprofen (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen (up to 600 mg daily)
Study: 25881455
Drug: Chuanhuang No.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chuanhuang No.1 Recipe (CHR), 400 mL each time, one dose per day for 24 weeks
Study: 25881455
Drug: Losartan Potassium,
Normalized name: Losartan Potassium, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan Potassium, 50-100 mg per day for 24 weeks
Study: 11871364
Drug: Short-acting beta2-agonist
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting beta2-agonist (salbutamol, n=41)
Study: 11871364
Drug: Long-acting beta2-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta2-agonist (formoterol, n=46)
Study: 24621065
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg zinc daily for 12 weeks
Study: 23909679
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol treatment
Study: 11359594
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with intravenous propofol sedation (SA)
Study: 9304087
Drug: 2% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% clindamycin vaginal cream (100 mg/day for 7 days)
Study: 9304087
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin (2 g/day for 7 days)
Study: 29108797
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor plus NRTI group (lopinavir 400 mg with ritonavir 100 mg, twice per day plus two or three clinician-selected NRTIs)
Study: 29108797
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor plus raltegravir group (lopinavir plus raltegravir 400 mg twice per day)
Study: 29108797
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor monotherapy group (lopinavir monotherapy plus raltegravir induction for first 12 weeks, re-intensified to combination therapy after week 96)
Study: 25357218
Drug: Osteopathy (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathy (3 sessions at 15, 30, and 45 days after infliximab infusion)
Study: 18375318
Drug: ACE‐Is (ramipril,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE‐Is (ramipril, 1.25 mg twice a day from the day after the operation)
Study: 15262194
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20mg with placebo (group AP)
Study: 12577430
Drug: Naoreqing (NRQ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoreqing (NRQ) oral liquid
Study: 12577430
Drug: Naoreqing (NRQ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoreqing (NRQ) oral liquid plus western medicine
Study: 9701524
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg b.d. (group PMC 500)
Study: 9701524
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg b.d. (group PMC 250)
Study: 29036256
Drug: Oral minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral minocycline HCl extended-release tablets (approximately 1 mg/kg)
Study: 29036256
Drug: Topical minocycline
Normalized name: minocycline Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minocycline foam 4% (4-g maximal-use dose) applied once daily for 21 days
Study: 19221257
Drug: Whole-body irradiated
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body irradiated with a 0.7-MED of UV-B daily on 10 consecutive days followed by a single dose of 3 MEDs on a small body area
Study: 19221257
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body irradiated with 120 J/m2 solar-simulated radiation for 10 consecutive days, then single-dose UV-B exposure of 3 MEDs on a small body area after 24 hours
Study: 19221257
Drug: Irradiated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiated with a single UV-B dose of 3 MEDs on a small body area
Study: 19221257
Drug: Irradiated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiated with a single UV-B dose of 4 MEDs on a small body area
Study: 14656270
Drug: Adjuvant platinum-containing
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant platinum-containing chemotherapy
Study: 7510316
Drug: Tianeptine 12.5
Normalized name: tianeptine 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine 12.5 mg single dose and 12 weeks treatment up to 37.5 mg daily
Study: 3774011
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course of chemotherapy (cyclophosphamide, 5 mg/kg/day for 6 days iv)
Study: 3774011
Drug: Continued chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued chemotherapy for 1 year (for node-positive patients)
Study: 27458288
Drug: Selinexor (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (60 mg flat dose) administered twice per week (days 1 and 3) on a 3 weeks on, 1 week off schedule
Study: 20467648
Drug: No HBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: No HBO therapy
Study: 8876070
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg cetirizine (CTZ)
Study: 8876070
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg pseudoephedrine retard (PER)
Study: 8876070
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5 mg cetirizine and 120 mg pseudoephedrine retard (COM)
Study: 1362377
Drug: Vasoactive agents
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive agents
Study: 3925486
Drug: Diazepam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.25 mg/kg oral)
Study: 18559301
Drug: Valerian/hops fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian/hops fluid extract (2 ml diluted in 50 ml water, administered 15 minutes before EEG recording)
Study: 18559301
Drug: Placebo (similar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similar smelling placebo, 2 ml diluted in 50 ml water, administered 15 minutes before EEG recording)
Study: 11217678
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg DKPT t.i.d. (n = 97)
Study: 11217678
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg TRAM t.i.d. (n = 95)
Study: 9291421
Drug: BAY x
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY x 7195 (500 mg, single oral dose)
Study: 2873760
Drug: Atracurium, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium, 1.0 mg/kg
Study: 2873760
Drug: Vecuronium, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium, 0.1 mg/kg
Study: 2873760
Drug: Vecuronium, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium, 0.2 mg/kg
Study: 2873760
Drug: Atracurium, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium, 1.0 mg/kg (rapid sequence induction)
Study: 2873760
Drug: Vecuronium, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium, 0.2 mg/kg (rapid sequence induction)
Study: 29470308
Drug: IAI 2
Normalized name: Intravitreal aflibercept injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAI 2 mg every 4 weeks until Week 16 then 8-week dosing (2q8)
Study: 26927286
Drug: Acetaminophen 4g
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 4g daily for 7 days
Study: 17042248
Drug: Caffeinated tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated tube food (200 mg)
Study: 10775736
Drug: Controlled-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release oxybutynin
Study: 9068331
Drug: Propofol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (n = 26, median dose 157 mg over 70 s)
Study: 9068331
Drug: Etomidate (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (n = 25, median dose 16.2 mg in 57 s)